Alexandre Reuben - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Alexandre Reuben

Showing results (131-140 of 133) with videos related to

Pageof 14

Sort By:

You have reached the last page of results.This site can display upto 133 results.

Nature Medicine|February 19, 2021

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.

Nature|January 17, 2020

B cells and tertiary lymphoid structures promote immunotherapy responseBeth A Helmink, Sangeetha M Reddy, Jianjun Gao, et al.

Nature Medicine|July 9, 2021

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeMiles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.

Pageof 14

Search research articles

Showing results (131-140 of 133) with videos related to

Sort By:

Pageof 14

You have reached the last page of results.This site can display upto 133 results.

Nature Medicine|February 19, 2021

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.

Nature|January 17, 2020

B cells and tertiary lymphoid structures promote immunotherapy responseBeth A Helmink, Sangeetha M Reddy, Jianjun Gao, et al.

Nature Medicine|July 9, 2021

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeMiles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.

Pageof 14